Article
NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels.
Department of Pharmacology SL-83, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA.
Journal of Pharmacology and Experimental Therapeutics (impact factor:
3.83).
05/2004;
309(1):193-9.
DOI:10.1124/jpet.103.060814
pp.193-9
Source: PubMed
-
Citations (0)
-
Cited In (0)
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
active metabolite
block recombinant alpha(1)G T-type channels
Ca2+ channel antagonist
causes L-type Ca2+ channel inhibition
high-voltage-activated Ca2+ channels
high-voltage-activated channels
INS-1 cells
insulin-secreting cell line
intracellular hydrolysis
L-type Ca2+ channels
mass spectrometry
mibefradil metabolite
modified structure
nonhydrolyzable analog
steady-state inactivation curve
T-type Ca2+ channels
T-type Ca2+ current
T-type Ca2+ current activity
T-type Ca2+ currents
voltage-dependent activation